One year of mepolizumab. Efficacy and safety in real-life in Italy-Reference-Cited by-同舟云学术

One year of mepolizumab. Efficacy and safety in real-life in Italy

Published:2019-10 Issue: Volume:58 Page:101836
ISSN:1094-5539
Container-title:Pulmonary Pharmacology & Therapeutics
language:en
Short-container-title:Pulmonary Pharmacology & Therapeutics

Author:

Bagnasco Diego,Caminati Marco,Menzella Francesco,Milanese Manlio,Rolla Giovanni,Lombardi Carlo,Bucca Caterina,Heffler Enrico,Paoletti Giovanni,Testino Elisa,Manfredi Andrea,Caruso Cristiano,Guida Giuseppe,Senna Gianenrico,Bonavia Marco,Riccio Anna Maria,Canonica Giorgio Walter,Passalacqua Giovanni

Funder

CIPRO (Centro Interprofessionale Pneumologico Ricerca ed Organizzazione), Genoa

Publisher

Elsevier BV

Subject

Pharmacology (medical),Biochemistry (medical),Pulmonary and Respiratory Medicine

Reference39 articles.

1. Global asthma prevalence in adults: findings from the cross-sectional world health survey;To;BMC Public Health,2012

2. Anti-IL-5 therapy in patients with severe eosinophilic asthma - clinical efficacy and possible criteria for treatment response;Drick;BMC Pulm. Med.,2018

3. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma;Chung;Eur. Respir. J.,2014

4. GINA 2017 guidelines;Page;Glob. Initiat. Asthma,2017

5. Nasal polyps in patients with asthma: prevalence, impact, and management challenges;Langdon;J. Asthma Allergy,2016

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Airway remodelling in asthma and the epithelium: on the edge of a new era;European Respiratory Journal;2024-04

2. Long-term safety, durability of response, cessation and switching of biologics;Current Opinion in Pulmonary Medicine;2024-03-01

3. The phenotypic heterogeneity of obese and nonobese patients with severe asthma and comparison of omalizumab–mepolizumab treatment efficiency in these patients;Medicine;2023-10-27

4. Long-Term Efficacy of Mepolizumab at 3 Years in Patients with Severe Asthma: Comparison with Clinical Trials and Super Responders;Biomedicines;2023-08-30

5. Comparison of omalizumab and mepolizumab treatment efficacy in patients with atopic and eosinophilic “Overlap” severe asthma: Biological agent preference in atopic-eosinophilic severe asthma;Medicine;2023-05-05